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Background: Intratumoral heterogeneity is a major obstacle for the treatment of cancer, as the presence of even
minor populations that are insensitive to therapy can lead to disease relapse. Increased clonal diversity has been
correlated with a poor prognosis for cancer patients, and we therefore examined genetic, transcriptional, and
functional diversity in metastatic melanoma.
Methods: Amplicon sequencing and SNP microarrays were used to profile somatic mutations and DNA copy number
changes in multiple regions from metastatic lesions. Clonal genetic and transcriptional heterogeneity was also assessed in
single cell clones from early passage cell lines, which were then subjected to clonogenicity and drug sensitivity assays.
Results: MAPK pathway and tumor suppressor mutations were identified in all regions of the melanoma metastases
analyzed. In contrast, we identified copy number abnormalities present in only some regions in addition to
homogeneously present changes, suggesting ongoing genetic evolution following metastatic spread. Copy number
heterogeneity from a tumor was represented in matched cell line clones, which also varied in their clonogenicity and
drug sensitivity. Minor clones were identified based on dissimilarity to the parental cell line, and these clones were the
most clonogenic and least sensitive to drugs. Finally, treatment of a polyclonal cell line with paclitaxel to enrich for
drug-resistant cells resulted in the adoption of a gene expression profile with features of one of the minor clones,
supporting the idea that these populations can mediate disease relapse.
Conclusion: Our results support the hypothesis that minor clones might have major consequences for patient
outcomes in melanoma.
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Cancer is caused by successive genetic change that dis-
rupts regulatory processes and endows cells with sur-
vival and growth advantages [1]. Ongoing mutation
provides a substrate on which selection operates, with
aberrations yielding increased fitness leading to an in-
creasing proportion of affected cells and their progeny
[2]. Clonal genetic diversity of cancer cells has been* Correspondence: jonathan.cebon@ludwig.edu.au
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reproduction in any medium, provided the orcorrelated with poor prognosis for cancer patients [3]. In
pancreatic [4] and renal cancer [5], exome sequencing of
different regions of primary and metastatic tumors has
identified heterogeneity in sequence mutations. These
findings are of particular interest given the current focus
in oncology on using drugs that target specific mutant
proteins and downstream signaling nodes.
Melanomas can contain tens of thousands of mutations
[6,7]. While metastases can be genetically divergent from
primary tumors [8,9], heterogeneous BRAF mutation status
has also been demonstrated between individual circulating
melanoma cells [10]. In primary and metastatic lesions,
Takata et al. [9] demonstrated different clonal heterogeneity
using microsatellite markers mapping to chromosomes 6q,td. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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present NRAS mutation was reported in a progressing le-
sion following treatment with vemurafenib [11]. However,
there has been no genome wide characterization of genetic
heterogeneity within metastatic melanoma lesions to date.
Likewise it is unknown whether cell lines retain genetic het-
erogeneity representative of the original tumor.
In this study we assessed genetic heterogeneity in meta-
static melanomas and derived cell lines at the level of copy
number abnormalities and sequence mutations in a cancer-
focused panel of genes. We found significant copy number
heterogeneity in tumors and cell lines, and went on to
demonstrate that much of the functional heterogeneity we
observed could be attributed to relatively minor clones.
Results
Regional DNA copy number heterogeneity in metastatic
melanoma
Eight regions of lymph node metastasis Tumor 1 were
assessed for the presence of chromosomal amplifications
and deletions. DNA extracted from cores taken from three
separate FFPE tissue blocks was analyzed using theFigure 1 Copy number heterogeneity between different regions of a
of section of FFPE block from Tumor 1 before coring and after coring. Inse
fragment used for DNA isolation. Scale bar next to whole section represents 1
and heatmap of copy number data from Tumor 1 cores. Black regions represe
red deletions.Affymetrix Oncoscan 2.0 platform. H&E staining was used
to identify regions composed primarily of tumor cells prior
to coring, with sections taken from immediately below ana-
lyzed fragments to control for contaminating normal tissue
(Figure 1A and Additional file 1: Figure S1). Hierarchical
clustering of DNA copy number profiles separated the
samples into two groups, with visual inspection of the
heatmap showing that cores taken from the same tissue
block often demonstrated very different patterns of amplifi-
cations and deletions (Figure 1B). Statistically significant re-
gions of amplification and deletion were next defined using
a segmentation algorithm, and the occurrence of specific
aberrations compared across the tumor regions. The sam-
pled tumor regions harbored between 44 and 133 signi-
ficant regions of copy number changes (Figure 2A),
encompassing between 23 and 59 percent of the genome
(Figure 2B). The greatest proportion of changes was
present in all regions; however, many aberrations were
present in only one or two cores (Figure 2C). Heterogeneity
was observed in genomic regions containing genes with
demonstrated potential to impact melanoma biology, such
as the high level amplification (greater than 5 copies) ofmetastatic melanoma tissue sample. A) Representative H&E staining
rts in the ‘after’ panel are H&E stains from the bottom of the core
mm, bars next to cores represent 100 μm. B) Hierarchical clustering
nt normal copy number (2), green represents amplifications,
Figure 2 Attributes of copy number variation in different regions of Tumor 1. A) Total number of copy number abnormalities identified in
each core. B) Percent of genome affected by copy number abnormalities identified in each core. C) Proportion of cores in which the copy
number abnormalities were identified.
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2. This region encompasses the gene for histone methyl-
transferase SETDB1, recently identified as an oncogene
[12] and a candidate susceptibility gene [13] in melanoma.
Detailed probe level and segmentation results from
Chromosome 1 and Chromosome 17 are shown in Figure 3
and Additional file 2: Figure S2 respectively.
The Oncoscan 2.0 platform also includes probes that
test for 541 individual mutations in 62 well known can-
cer genes, with the presence of a mutation indicated by
high probe intensity. Despite the presence of mutation-
specific probes with highly heterogeneous intensity, no
heterogeneous mutations could be validated by capillarysequencing. Similar results were obtained following Ion
Torrent sequencing of amplicons covering a similar panel
of cancer genes, which was performed in regions from two
additional melanomas (Tumors 2 and 3). These experi-
ments are described in the Additional file 3, in Additional
file 4: Table S1, and in Additional file 5: Figures S3 and
Additional file 6: Figure S4.
Early passage metastatic melanoma cell lines retain
genetic heterogeneity
The copy number profiles of a cell line derived from
Tumor 1 (LM-MEL-62), ten single cell clones derived
from LM-MEL-62, and a fresh frozen tumor fragment of
Figure 3 Copy number heterogeneity of Chromosome 1 in different regions of Tumor 1. Segmentation results for all eight cores are
shown in the top panel; amplification in red, deletions in blue. The plots below show results for Block 1–2 Core 1 and Block 1–2 Core 2 in greater
detail. Regions defined by segmentation are highlighted by solid red and blue bars as above. Small dots represent the copy number values of
individual array probes, while larger dots represent smoothed data resulting from averaging results from 30 adjacent probes. The high level
amplification of 1q21, encompassing SETDB1, can clearly be seen adjacent to the centromere in Core 2 of Block 1–2.
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All cell line-derived samples clearly shared many com-
mon copy number changes with the original tumor, such
as gain of 6p (Figure 4A). The clones harbored between
55 and 69 copy number changes, which represents sig-
nificantly less variation than was observed in the differ-
ent regions of Tumor 1 (Figure 4B). Nevertheless, the
cell clones were also heterogeneous for many of the
detected aberrations (Figure 4C), and the LM-MEL-62
clones displayed heterogeneity at chromosome regions
similarly affected in the archival FFPE tumor material(Figure 5A and B). This suggests that early passage mel-
anoma cell lines are polyclonal, and that they can retain
or recapitulate genetic heterogeneity representative of
that found in the patient’s tumor.
We generated copy number profiles for clones from
two other cell lines derived from Tumor 2 and Tumor 3
(Figure 6A & B respectively). Clones from both cell lines
had copy number changes that were identified in all
clones, and some that were present in some clones but
not others (Figure 6C & D). The clones from the three
cell lines assessed contained significantly different
Figure 4 LM-MEL-62 features clonal copy number heterogeneity. A) Hierarchical clustering and heatmap of copy number data from single
cell clones of LM-MEL-62, the parental cell line, and a fresh frozen fragment of Tumor 1. Black regions represent normal copy number (2), green
represents amplifications, red deletions. B) number of copy number abnormalities found in from single cell clones of LM-MEL-62, the parental cell
line, and a fresh frozen fragment of Tumor 1. C) Proportion of clones in which specific copy number changes were identified.
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p < 0.0001; Figure 6E), however they did not differ in
the proportion of the genome affected by copy number
abnormalities (one way ANOVA, p = 0.165; Figure 6F).
The copy number profile of the parental cell lines rep-
resent an average signal derived from all cells in the line.
Therefore, the clones with profile closest to the parental
line as determined by clustering (such as Clones 7, 8,
and 9 in LM-MEL-62) represent the most prevalent or
dominant clone(s), with the others representing rela-
tively minor populations. This information provided the
opportunity to assess functional differences between
dominant and minor cell populations.
Single cell clones from a metastatic melanoma cell line
are functionally heterogeneous
In order to assess whether the genetic heterogeneity ob-
served in cell lines was accompanied by functional vari-
ation, we compared clones from LM-MEL-62 to the
parental line. Clear differences were seen in their sensi-
tivity to cytotoxic drugs paclitaxel (Figure 7A) and 5-
fluorouracil (5FU) (Figure 7B), and in their ability toform adherent colonies from single cells (Figure 7C),
and in soft-agar (Figure 7D). Clones with copy number
profiles that did not cluster with the parental line (pre-
sumably less prevalent in the pooled population) were
those that demonstrated the strongest behaviors. For ex-
ample, Clone 3 was the most clonogenic, and Clones 1
and 10 were the least sensitive to cytotoxic drugs. Clone
2 was not assessed for drug sensitivity, and Clone 10
was not assessed in soft-agar assays, as they ceased pro-
liferating before the assays could be performed. This in-
dicates that the clones also differed in their long-term
replicative potential following isolation.
Single cell clones from metastatic melanoma cell lines
display evidence of differential pathway activation based
on gene expression profiling
The gene expression profiles of LM-MEL-62 and derived
clones were assessed using Illumina HT-12 microarrays.
Unsupervised hierarchical clustering placed some clones
into different clusters than observed based on copy num-
ber data, but Clones 7, 8, and 9 still clustered with the par-
ental cell line (Figure 8A). Again as the profile of the
Figure 5 In vitro clonal copy number heterogeneity can recapitulate heterogeneity found in the original tumor. Comparison of
amplifications, deletions, and break points identified on Chromosome 13 (A) and Chromosome 19 (B) in FFPE cores from multiple regions of
Tumor 1, and matched cell line LM-MEL-62, derived single cell clones, and independent fresh frozen fragment of Tumor 1.
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supports Clones 7, 8, & 9 as the most prevalent cell types.
The clones segregated into three clusters, which we
compared using gene set enrichment analysis (GSEA)
(Table 1, full results in Additional file 7: Table S2). Inter-
estingly, the clones with the expression profile most
similar to the parental cell line expressed genes typical
of aggressive metastatic melanoma. Their expression
profile was similar to one derived by comparing melan-
oma metastasis to primaries, and from the primaries of
patients that later developed metastases. In contrast, the
other groups of clones over-expressed genes related to
the activity of specific signaling pathways, such as MET
and PI3K, and genes induced by interferon-alpha.
Notably, the expression of interferon-inducible genes
has been associated with decreased sensitivity to paclitaxel[14,15]. Consistent with this, the clone expressing the
highest levels of inflammation and interferon-inducible
genes (Clone 1; Figure 8B) was significantly less sensitive
to paclitaxel than the parental cell line (Figure 7A).
Treating parental LM-MEL-62 with increasing concentra-
tions of paclitaxel likewise enriched for a cell population
that expressed higher levels of several of interferon indu-
cible genes from the enriched gene sets (Figure 8C). This
demonstrates that a phenotype that was present in only a
minority of cells has the potential to play an important
role in survival and re-growth during and after drug
treatment.
Discussion
Excision of localized primary melanomas provides a
curative treatment for most patients; however, survival
Figure 6 Copy number heterogeneity in single cell clones from metastatic melanoma cell lines LM-MEL-34 and LM-MEL-42. Hierarchical
clustering and heatmap of copy number data from single cell clones of LM-MEL-34 (A) and LM-MEL-42 (B) along with the parental cell lines.
LM-MEL-34 was established from Tumor 2, while LM-MEL-42 was established from Tumor 3. Black regions represent normal copy number (2),
green represents amplifications, red deletions. C) Proportion of clones from LM-MEL-34 in which specific copy number changes were identified.
D) Proportion of clones from LM-MEL-42 in which specific copy number changes were identified. E) Total number of copy number abnormalities
found in clones from three metastatic melanoma cell lines. F) Percent genome affected by copy number abnormalities found in clones from
three metastatic melanoma cell lines.
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tematic therapies remains poor. Clonal diversity has
been associated with poor prognosis and treatment re-
sistance in cancer [3], and we therefore examined gen-
etic diversity in melanoma metastases.
We found that presumed disease drivers, such as MAPK
activating mutations, were homogeneously present in
metastatic lesions. In contrast we identified significant het-
erogeneity in chromosomal aberrations in different re-
gions of a lymph node metastasis, and in clones from
several cell lines, suggesting that genetic evolution con-
tinues in metastases. The clones from LM-MEL-62
contained chromosomal heterogeneity at regions similar
to those in the original tumor, and were additionallyheterogeneous in their gene expression profile and cellular
behaviors.
This intratumoral heterogeneity becomes significant if it
provides populations of cells capable of surviving and pro-
liferating following changes in selective pressures, such as
during drug treatments. As a model of this possibility, we
selected for a population of cells resistant to paclitaxel,
and observed the outgrowth of cells with an interferon-
inducible gene expression signature originally found in
only a minor population of paclitaxel-insensitive cells in
the parental cell line. A recent study in which clonal popu-
lations of colorectal cancer cells were tracked in xeno-
grafts likewise found that clones that were initially rare
went on to become the dominant cell population
Figure 7 Functional heterogeneity between clones of LM-MEL-62. Sensitivity of LM-MEL-62 and derived clones to 20nM paclitaxel (A) and
200μM 5FU (B). Values plotted represent a ratio of the MTS absorbance of drug treated samples to vehicle treated controls. Data from Clones
were compared to parental LM-MEL-62 by one-way ANOVA with Dunnett’s Multiple Comparison Test. P-value < 0.05 – *; < 0.001 – ***. C) Single
cell colony formation assay to measure growth independence of LM-MEL-62 and derived clones. Clones were compared to parental LM-MEL-62
using a one-way ANOVA with Dunnett’s Multiple Comparison Test. P-value < 0.001 – ***. D) Soft-agar colony formation assays to measure
anchorage independent growth and clonogenicity of LM-MEL-62 and derived clones. Clones were compared to parental LM-MEL-62 using a one-
way ANOVA with Dunnett’s Multiple Comparison Test. P-value < 0.05 – *; < 0.001 – ***.
Anaka et al. BMC Medical Genomics 2013, 6:40 Page 8 of 13
http://www.biomedcentral.com/1755-8794/6/40following treatment with chemotherapy [16]. Likewise our
results complement a recent report stating that based on
the number of cells in established tumors and a conserva-
tive mutation rate, clones containing mutations conferring
drug resistance will inevitably be present pre-treatment
[17]. In our study other minor clones expressed genes re-
lated to the PI3K and MET pathways, which have been as-
sociated with resistance to vemurafenib [18,19]. The
presence of minor clones with higher baseline activity of
these pathways could contribute to targeted therapy resist-
ance, much as we observed with paclitaxel treatment.
Finally it is important to note that despite using two
independent technologies to profile somatic mutations,
both of which were designed for use with DNA from
formalin fixed tissues, we encountered many false posi-
tives. Although this issue might be avoided by using fro-
zen tissue, formalin fixation will remain a favored way to
preserve samples due to ease of storage and other ad-
vantages. We therefore urge caution when using these
samples with platforms like the Ion Ampliseq panels, as
fixation-related artifacts may will likely lead to false posi-
tive variants calls.Conclusion
Metastatic melanomas feature significant genetic and
phenotypic heterogeneity, with the potential to confound
the success of many therapies. Genetic heterogeneity
represents an obstacle for mutation-directed personal-
ized cancer medicine, albeit one which might be com-
pensated for by analyzing multiple biopsies at sufficient
depth to identify rare variants. However, drug resistance
can have its basis in genetic, epigenetic, and stochastic
variation, and the transcriptomic and functional variation
we identified in this study suggests that these mechanisms
are relevant in metastatic melanoma. As accounting for
these additional levels of regulation in multiple biopsies
would be exceedingly challenging, targeting multiple
tumor clones might best be accomplished using immuno-
therapy approaches such as tumor-lysate stimulated adop-
tive cell transfer or immune regulatory check point
blockade agents such as ipilimumab. These therapies have
intrinsic potential to induce responses against a broad
range of antigens specific to a patient’s tumor, which
would circumvent the type of sampling error caused by
intratumor heterogeneity that must be confronted in
Figure 8 Gene expression heterogeneity in single cell clones of metastatic melanoma cell line LM-MEL-62. A) Hierarchical clustering
based on the 1000 genes with the greatest variants amongst all samples. B) Hierarchical clustering of the LM-MEL-62 and derived clones using
genes from MSigDB gene set M9221 with positive enrichment in Clones 1, 5, & 6 (Table 2). C) Expression of interferon-inducible genes was
significantly increased in a paclitaxel-resistant LM-MEL-62 derivative relative to the parental cell line (P = 0.0012; paired t-test) based on
QPCR analysis.
Table 1 Selected gene sets associated with clustering-defined groups of clones of melanoma cell line LM-MEL-62
Gene set description NES FDR MSigDB ID
Genes sets enriched in Clones 4,7,8,9
Up-regulated in melanoma patients with distant metastasis within 4 years 2.60 0.000 M6387
DNA repair and replication genes up-regulated in melanoma patients who relapsed 2.46 0.000 M2431
Up-regulated in metastases to primary melanomas 2.14 0.000 M5740
Genes sets enriched in Clones 1,5,6
Genes up-regulated in fibroblasts after interferon alpha treatment 2.10 0.000 M9221
Tumor necrosis factor pathway 1.95 0.003 M18030
NOTCH signaling 1.89 0.006 M7946
Genes sets enriched in 2,3,10
Genes up-regulated in MET over-expressing colon cancer xenografts 2.23 0.000 M3231
Genes involved in G beta:gamma signaling through PI3Kgamma 1.79 0.046 M14301
NES – normalized enrichment score. FDR – false discovery rate.
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lysis of biopsies.
Methods
Tumor material and cell lines
Melanoma lymph node metastases and derived early pas-
sage cells lines from three patients were analyzed for re-
gional and clonal differences in this study. Following
pathological examination tumors were used for cell line
generation, archived as formalin fixed paraffin embedded
(FFPE) tissue blocks, and nucleic acid extraction performed
from snap frozen fragments when sufficient material was
available. Tissue donors consented for tissue collection and
protocols were approved by the Austin Health Human Re-
search Ethics Committee, Melbourne, Australia. The clin-
ical characteristics of all samples are listed in the Table 2.
In addition to a splenic lymph node lesion, the patient as-
sociated with Tumor 3 had a hepatic artery lymph node
deposit resected concurrently, which was labeled as Tumor
3 Block 2–4.
The FFPE blocks from an individual tumor represent
contiguous transverse slices; however, tissue orientation
was not recorded during embedding. Hematoxylin and
eosin (H&E) staining was used to determine regions of
viable tumor cells in each tissue block, and 3mm cores
were then removed from target regions using a tissue
microarrayer. The tip (~2 mm) of the cylindrical core
was removed with a sterile scalpel blade and used for
DNA extraction. For the cores from Tumor 1 used for
DNA copy number analysis, the remaining core was em-
bedded into a recipient block of paraffin so that the
upper surface could be sectioned and the proportion of
tumor cells analysed. Cores from Tumors 1 and 2 were
used only for sequencing-based mutation profiling.
The melanoma cell line establishment, culture methods,
and RF10 growth media formulation used by our labora-
tory have previously been reported [20]. Single cell-
derived clonal sublines (clones) were isolated through
low-density plating and colony isolation using 5 mm
plastic cylinders.
Microarray analysis
Nucleic acids were extracted from cell line pellets and
fresh frozen tumor pieces using the AllPrep Mini Kit
(Qiagen). All extractions for cell line clones were
performed before the clones had been passaged five
times in culture. DNA extraction from FFPE samplesTable 2 Tumor and cell line characteristics
Site of disease Stage at
Tumor 1 Axillary lymph node IIIc
Tumor 2 Axillary lymph node IIIb/c
Tumor 3 Splenic lymph node IVcused the Arcturus Picopure DNA Extraction kit (Applied
Biosystems) with a 24 hour Proteinase K incubation,
followed by further purification using DNeasy columns
(Qiagen).
DNA from cell lines, patient blood, and fresh frozen ma-
terials was analyzed on Illumina Human610-Quad genotyp-
ing arrays at the Memorial Sloan-Kettering Cancer Center
Genomics Core Laboratory and imported into Partek
Genomics Suite (PGS). Data from blood samples was used
to create paired copy number data for each patient. Seg-
mentation algorithm settings were: minimum markers 15,
p-value 0.0001, expected range 0.5, amplification signal-
to-noise ratio 0.4, deletion signal-to-noise ratio 0.8.
DNA from FFPE samples was analysed using the
Oncoscan Express 2.0 service from Affymetrix, which
employs arrays containing 334 000 copy number probes,
and 541 probes specific for somatic cancer mutations.
Oncoscan copy number data were processed and nor-
malized by Affymetrix according to previously published
methods [21], and copy number is calculated in refer-
ence to Oncoscan data from an Affymetrix panel of nor-
mal reference samples. Segmentation algorithm settings
were: minimum markers 10, p-value 0.0001, expected
range 0.5, amplification signal-to-noise ratio 0.4, deletion
signal-to-noise ratio 1.0.
Hierarchical clustering of copy number data used
Euclidian distance and average linkage.
Illumina HT-12 gene expression arrays were processed
at the Australian Genome Research Facility. Using R and
the Bioconductor package Limma [22], raw data were
background corrected using the normexp function, log-
transformed, and quantile normalized. Hierarchical cluster-
ing in Partek GS used Euclidian distance and average link-
age. Gene Set Enrichment Analysis (GSEA) [23] employed
gene set permutation, a 5% FDR cutoff, and gene sets from
the MSigDB database v3.0, category C2.
The Illumina HT-12 gene expression array and
Illumina 610-Quad SNP array data are available in the
ArrayExpress database (www.ebi.ac.uk/arrayexpress) under
accession number E-MTAB-1753.
Mutation profiling by amplicon sequencing
Somatic mutation profiling using the Ion AmpliSeq Can-
cer Panel, Ion Torrent sequencing, and the Ion Variant
Caller (Life Technologies) was performed by AIT Bio-
tech (Singapore). Libraries were barcoded using the Ion
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Ion 318 chips (all Life Technologies). Default Ion Variant
Caller settings were employed, with the exception of a
SNP QV minimum of 14. This value was chosen as it
eliminated false negatives in the identification of BRAF
mutations in Tumor 1, which was previously confirmed
via capillary sequencing. Known SNPs and synonymous
changes were removed, as were low-confidence inser-
tions and deletions associated with homopolymer runs
were also disregarded due to known issues with false
positives using this sequencing platform [24]. Variants
were analyzed using the Ensemble Variant Effect Pre-
dictor [25], which included SIFT [26] and PolyPhen [27]
predictions of the consequence of a sequence variant on
protein function. The amplicon sequencing reads and vari-
ant prediction results are available in the ArrayExpress
database (www.ebi.ac.uk/arrayexpress) under accession
number E-MTAB-1794.
Validation of high frequency variants was performed
using standard capillary sequencing. PCR products cov-
ering mutations indentified by Ion Torrent sequencing
were amplified using GoTaq mastermix (Promega). PCR
products were sequenced at AGRF, using a 3730xl se-
quencer and BigDye Terminator v3.1 chemistry (both
Applied Biosystems). Primers (all shown 5′ to 3′) used
to validate the BRAF and NRAS mutations in Tumor 1
were as follows: BRAF G649E Forward Primer –
TACCATGCCACTTTCCCTTG, Reverse Primer TTTT
CTGTTTGGCTTGACTTGA; NRAS G12S Forward
Primer – GGTTTCCAACAGGTTCTTGC, Reverse Pri-
mer CTCACCTCTATGGTGGGATCA.
Validation for low frequency variants was perfor-
med by high-resolution melt (HRM) analysis on a
Rotor-Gene Q (Qiagen), before and after uracil-DNA
glycosylase (UDG) treatment to control for FFPE se-
quence artifacts as previously described [28]. The HRM
primer sequences for FGFR3 exon 6 variant analysis
were F 5′-CAGTGGCGGTGGTGGTGAGG-3′ and R
5′-ACCTTGCAGTGGAACTCCACGTC-3′. PCR cyc-
ling and HRM was performed on the Rotor-Gene Q
(Qiagen, Hilden, Germany). The reaction mixture in a
final volume of 20 μL was prepared as follows; 1 × PCR
buffer, 2.5 mM MgCl2, 400 nM of each primer, 10 ng of
FFPE DNA, 200 μM of dNTPs, 5 μM of SYTO9
(Invitrogen), and 0.5 U of HotStarTaq polymerase
(Qiagen). The PCR cycling and melting conditions were
as follows; an initial incubation at 95°C for 15 min,
followed by 55 cycles of 96°C for 15 s, 70°C for 20 s,
72°C for 30 s; one cycle of 97°C for 1 min and a melt
from 70°C to 95°C rising 0.2°C per second. All samples
were tested in duplicate. For UDG treatment, 0.5 × UDG
buffer and 0.5 U of uracil-DNA glycosylase (New England
Biolabs) were added to the PCR master mix. The same
PCR conditions were used except an addition of initialincubation at 37°C for 30 min before the activation of
HotStarTaq polymerase.
A PIK3CA E549D mutation detected at a low fre-
quency (4%) in the Core 2 of Tumor 2 by AmpliSeq was
analysed by limited copy number (LCN)-HRM [29]. The
reaction mixture and cycling conditions were those used
for the FGFR3 HRM assay with UDG treatment, except
with an annealing temperature of 60°C and 100 pg of
template were used. The Core 2 sample was tested in
100 replicates, but no variants were identified. The pri-
mer sequences for PIK3CA exon9 analysis were F 5′-
AAGAACAGCTCAAAGCAATTTCTACAC-3′ and R
5′-AATCTCCATTTTAGCACTTACCTGTGAC-3′.Functional assays
Single cell colony formation assays involved seeding sin-
gle cells in 96 well plates and counting the wells with
colonies of greater than 50 cells after four weeks.
Soft agar colony formation assays were performed in
24-well plates, with 2000 cells cultured in 500 μL of RF10
in 0.9% agarose, on a base layer 1.4% agarose in RF10.
500 μL of RF10 was layered over top of the agarose, and
plates were incubated for four weeks at 37°C. Colonies
were visualized and counted follow staining with MTT (3-
(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide;
Sigma Aldrich) for 60 minutes.
Paclitaxel and 5FU (Sigma Aldrich) were resuspended in
DMSO and sterile water respectively. Drug treatments
were applied to 7500 cells/well in 100 μL RF10 in 96-well
plates, with final concentrations of 20 nM paclitaxel and
200 μM 5FU. After 72 hours the amount of viable cells
remaining was quantified using the CellTiter AQueous
One Solution Cell Proliferation Assay (Promega). Values
from drug treatments were compared to vehicle-only con-
trols. A paclitaxel-resistant derivative of LM-MEL-62 was
created by exposing the parental cell line to drug for 72
hours, then allowing the cells to recover to confluence be-
fore re-treating. Three rounds were performed, with doses
doubled each time, with a final treatment of 40 nM. All
functional assays were performed on cell line clones be-
fore they had reached ten passages in culture.Quantitative PCR (QPCR)
cDNA was produced from RNA using the High Capacity
cDNA Reverse Transcription Kit (Applied Biosystems).
QPCR was performed using the QuantiFast SYBR Green
PCR Kit (Qiagen), with reactions run on a Stratagene
MX3005P thermocycler. Expression levels were normal-
ized to beta-actin. Primer sequences were as follows:
IFI6 F 5′- AGCAGCAGGTAGCACAAGAA-3′ and R
5′- GGGCTGAAGATTGCTTCTCTT -3′; IFI27 F 5′-
GCCACAACTCCTCCAATCAC-3′ and R 5′- ATCA
GCAGTGACCAGTGTGG -3′; MX1 F 5′- GATGAT
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AACAGACTCTTC -3′.
Additional files
Additional file 1: Figure S1. Shows H&E staining of sections from FFPE
blocks of Tumor 1. Inserts are H&E stains from the bottom of the core
fragment used for DNA isolation. Scale bar next to whole section
represents 1 mm, bars next to cores represent 100 μm. The section taken
from below Core 1 in Block 1–4 shows few tumor cells as the tissue in
this area was thin and the core passed through the remaining tissue. It is
worth noting that during the process of cutting sections for microscopy
several micrometers of thickness from the block were shaved off and
discarded before usable sections can be obtained. Thus the post coring
images are not exact representations of the tissue that was immediately
underneath that core fragments which were used for DNA extraction.
Additional file 2: Figure S2. Shows copy number heterogeneity of
Chromosome 17 in different regions of Tumor 1. Segmentation results for
all eight cores are shown in the top panel; amplification in red, deletions
in blue. The plots below show results for Block 1-1 Core 2 and Block 1-1
Core 3 in greater detail. Regions defined by segmentation are
highlighted by solid red and blue bars as above. Small dots represent the
copy number values of individual array probes, while larger dots
represent smoothed data resulting from averaging results from 30
adjacent probes.
Additional file 3: Supplementary Results.
Additional file 4: Table S1. Is an Excel file containing the results from
the Ion Ampliseq Cancer Panel variant analysis performed on DNA from
cores of Tumors 1, 2 and 3. Only one transcript was listed where the
amino acid change was equivalent across isoforms.
Additional file 5: Figure S3. Shows the identification and validation of
sequence mutations in cancer genes in different regions of metastatic
melanoma tissue samples. A) Fluorescence intensities for Oncoscan
probes specific for cancer mutations in cores from Tumor 1. B) Examples
of chromatograms from capillary sequencing of regions of NRAS and
MSH2 predicted to be mutated in Tumor 1 based on Oncoscan probe
intensities. C) Normalized HRM plots for PCR products covering FGFR3
exon 6 before and after UDG treatment.
Additional file 6: Figure S4. Shows H&E stainings of Tumors 2 and 3.
Only one block was available for Tumor 2. Tumor 3 Blocks 1–1 through
1–4 are from a spleen metastasis, Block 2–4 is a hepatic artery lymph
node metastasis removed concurrently from the same patient. White
numerals indicate regions where cores were removed.
Additional file 7: Table S2. Is an Excel file containing GSEA results
from comparing the clones in each cluster shown in Figure 8A.
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